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ABSTRACT
The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans. The high density of glycosyla-
tion on the viral spike limits enzymatic processing, resulting in numerous underprocessed oligomannose-type glycans. This ex-
tensive glycosylation not only shields conserved regions of the protein from the immune system but also acts as a target for anti-
HIV broadly neutralizing antibodies (bnAbs). In response to the host immune system, the HIV glycan shield is constantly
evolving through mutations affecting both the positions and numbers of potential N-linked glycosylation sites (PNGSs). Here,
using longitudinal Env sequences from a clade C-infected individual (CAP256), we measured the impact of the shifting glycan
shield during HIV infection on the abundance of oligomannose-type glycans. By analyzing the intrinsic mannose patch from a
panel of recombinant CAP256 gp120s displaying high protein sequence variability and changes in PNGS number and position-
ing, we show that the intrinsic mannose patch persists throughout the course of HIV infection and correlates with the number of
PNGSs. This effect of the glycan density on the processing state was also supported by the analysis of a cross-clade panel of re-
combinant gp120 glycoproteins. Together, these observations underscore the importance of glycan clustering for the generation
of carbohydrate epitopes for anti-HIV bnAbs. The persistence of the intrinsic mannose patch over the course of HIV infection
further highlights this epitope as an important target for HIV vaccine strategies.
IMPORTANCE
Development of an HIV vaccine is critical for control of the HIV pandemic, and elicitation of broadly neutralizing antibodies
(bnAbs) is likely to be a key component of a successful vaccine response. The HIV envelope glycoprotein (Env) is covered in an
array of host-derived N-linked glycans often referred to as the glycan shield. This glycan shield is a target for many of the re-
cently isolated anti-HIV bnAbs and is therefore under constant pressure from the host immune system, leading to changes in
both glycan site frequency and location. This study aimed to determine whether these genetic changes impacted the eventual
processing of glycans on the HIV Env and the susceptibility of the virus to neutralization. We show that despite this variation in
glycan site positioning and frequency over the course of HIV infection, the mannose patch is a conserved feature throughout,
making it a stable target for HIV vaccine design.
The HIV envelope glycoprotein (Env) is coated in a dense arrayof host-derived N-linked glycans. These glycans not only
shield conserved regions of the protein from neutralizing antibod-
ies (nAbs), but also act as targets for many of the most broad and
potent HIV neutralizing antibodies (1–6). Although HIV Env is
glycosylated by the host cell glycosylation machinery, Env glyco-
sylation has been shown to diverge from that typically observed in
mammalian cells (1, 7–15). The dense clustering of potential N-
linked glycosylation sites (PNGSs) sterically restricts the access of
glycan-processing enzymes in the endoplasmic reticulum (ER),
which results in a population of underprocessed oligomannose-
type glycans (7–17) that is a distinctive feature of HIV Env (2) and
is independent of producer cells (18). Site-specific analysis of the
glycans on recombinant gp120 shows that these oligomannose-
type glycans cluster together on the outer domain (OD) of gp120
(11, 13, 14, 19, 20), and this cluster is often referred to as the
mannose patch and is conserved across Env expression systems
(including virion-associated Env, SOSIP trimers, and recombi-
nant gp120 monomers) and different geographical clades (7, 15,
17, 18, 20, 21). During expression of both monomeric and trim-
eric gp120, this mannose population is termed the “intrinsic man-
nose patch” (1, 2, 18). In the native trimer, in addition to the
intrinsic mannose patch, further steric constraints on glycan pro-
cessing give rise to the so-called “trimer-associated mannose
patch” (1, 2, 18, 21, 22).
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Three main glycan-dependent sites of vulnerability on Env
have been identified so far. They include the N332 glycan/V3 loop,
which comprises the intrinsic mannose patch (recognized by, e.g.,
PGT128, PGT121, 10-1074, and PGT135 [5, 23–25]), but also the
N160 glycan/V1/V2 loops (recognized by, e.g., PG9, PG16,
PGT145, CAP256-VRC26.25, and CH04 [5, 26–28]) and the gly-
cans near the gp120/gp41 interface (recognized by, e.g., PGT151,
35O22, 8ANC195 [29–31]). Protein epitopes, such as the CD4
binding site and the membrane-proximal external region
(MPER), also show some dependence on N-linked glycosylation.
For example, the glycans situated on the rim of the CD4 binding
site can modulate the neutralization breadth and potency of CD4
binding site broadly neutralizing antibodies (bnAbs) (22, 32), and
the perturbation of gp41 glycosylation has been shown to influ-
ence the maximum neutralization of MPER bnAb 10E8 (33).
During infection, HIV Env is under constant pressure from the
host immune system, in particular neutralizing antibodies, and as
such, the location and frequency of PNGSs often change (3, 34).
This observation has led to the concept of the shifting or evolving
glycan shield (3). Recent studies aimed at mapping the develop-
ment of HIV bnAbs in HIV-infected patients has revealed the
importance of shifting PNGSs in bnAb development and has
shown that immune escape from strain-specific antibodies can
lead to formation of bnAb epitopes (35–37). For example, Moore
et al. showed in an HIV-infected individual that immune pressure
against the N334 glycan in a founder virus led to a shift to the
conserved N332 glycan position and subsequent development of
an N332-dependent bnAb response in that donor (35). Further,
removal of the N276 glycan has been shown to confer sensitivity to
germ line variants of CD4 binding site bnAbs, e.g., VRC01 and
NIH45-46, indicating that addition of this glycan as a potential
escape mechanism is critical for development of a broadly neutral-
izing CD4 binding site antibody response (38).
Studies comparing Env sequences from donor-recipient pairs
and large numbers of acute and chronic viruses have shown that
clade C transmitted viruses, and to a lesser extent clades A and D,
tend to have shorter variable loops and a lower number of PNGSs
than chronic viruses (39–43). These trends are observed for both
sexual transmission and mother-to-child transmission; however,
the significance of these differences for HIV transmission is not
fully understood. Analysis of longitudinal Env sequences over
years of HIV infection has shown that there is an increase in both
variable-loop length and PNGS frequency, which is reversed in the
later stages of infection (44, 45). It is proposed that this initial
increased glycosylation shields neutralizing protein epitopes from
the host immune system, which also wanes during late infection
(3, 34, 46, 47). Although these studies defined changes in the po-
sition and frequency of PNGSs over the course of HIV infection,
the effects of these changes on the composition of the glycans
present on Env, in particular the persistence of the intrinsic man-
nose patch, have not yet been determined.
Here, we use longitudinal Env sequences from a clade C-in-
fected donor, CAP256, to determine the change in glycan shield
composition and the abundance of oligomannose-type glycans in
the intrinsic mannose patch over the course of HIV infection and
to relate these changes to variable-loop length, frequency of
PNGSs, and neutralization sensitivity by a panel of HIV bnAbs.
The development of the bnAb response in donor CAP256 has
been extensively studied and is mediated by bnAbs directed to the
V1/V2 region on Env (27, 48, 49). This patient was infected with a
clade C virus and later became superinfected with a second, unre-
lated clade C virus between weeks 13 and 15, leading to Env re-
combination (27, 48, 49). The viral population early in infection
was predominantly made up of the superinfecting (SU) virus with
only the V1/V2 and gp41 C terminus mostly derived from the
primary infecting (PI) virus (49), but later in infection, multiple
different recombinant forms existed. Escape from the bnAb re-
sponse occurred through mutation in V2, in particular at residues
R166 and K169 (27, 48, 49).
Here, we show that although the number of PNGSs varies by
up to five, the intrinsic mannose patch is conserved across all
gp120 proteins. However, we observed variations in both the size
and composition of the intrinsic mannose patch. We show that
there is a strong correlation between the frequency of outer-do-
main PNGSs and the abundance of oligomannose-type glycans for
both CAP256 gp120s and a cross-clade panel of gp120s, highlight-
ing the importance of the glycan density for the restricted access by
glycan-processing enzymes. Although there were no strong corre-
lations across the full time period in this donor, a general increase
in total PNGSs was observed early in infection, and this increase
correlated with an increase in oligomannose-type glycans. This
was followed by a decline in PNGSs due to loss of glycans at the V3
base and a subsequent decline in oligomannose-type glycans,
which was associated with the development of neutralizing anti-
bodies to the C3V4 region. These results demonstrate the persis-
tence of the intrinsic mannose patch over the course of HIV infec-
tion and further highlight this region as a stable target for HIV
vaccine design strategies.
MATERIALS AND METHODS
Cloning and protein production. Cloning of the full-length soluble ect-
odomain of HIV-1 CAP256 gp120s (corresponding to amino acid resi-
dues 1 to 507, based on alignment to the HxB2 reference strain) into the
pHLsec expression vector (50) has been described previously (16, 51). The
CAP256 Env sequences were published previously (48, 49). The CAP256
proteins were expressed in the 293F variant of HEK 293T cells (Thermo-
Fisher Scientific), which is adapted for suspension culture, in 500-ml Er-
lenmeyer flasks with a vent cap (Corning). The cells were incubated at
37°C and 5% CO2 with shaking at 137 rpm as recommended by the man-
ufacturer. Briefly, 200-ml cultures were transfected with plasmids
(pHLSec) carrying the reporter gene expressing the protein using 293Fec-
tin (ThermoFisher Scientific). The culture supernatants were harvested 5
days after transfection, and the His-tagged proteins were purified by Ni2
affinity purification using a 5-ml HisTrap FF column (GE Healthcare).
The nickel-purified proteins were further purified using size exclusion
chromatography (SEC) on a Superdex 200 16/600 column (GE Health-
care). The monomeric fractions were collected, pooled, and analyzed us-
ing an SDS-PAGE 4% to 12% Bis-Tris NuPAGE gel (Invitrogen).
Glycan profiling by PNGase F release of N-glycans. N-glycans were
released from target glycoprotein immobilized in SDS-PAGE bands using
peptide-N-glycosidase F (PNGase F) (New England BioLabs) (52). Coo-
massie-stained gel bands were excised and washed alternately with aceto-
nitrile and water before being dried under vacuum. The gel pieces were
rehydrated in 20 mM sodium bicarbonate buffer, pH 7.0, and incubated
with PNGase F (1 l) for 16 h at 37°C. The released glycans were extracted
from the gel matrix by 3 washing steps with water.
Fluorescent labeling of N-linked glycans. The released glycans were
subsequently fluorescently labeled and purified as previously described
(53). The PNGase F-released N glycans were fluorescently labeled using
2-aminobenzoic acid (2-AA). The labeling mixture comprised 2-AA (30
mg/ml) and sodium cyanoborohydride (45 mg/ml) dissolved in a solution
of sodium acetate trihydrate (4% [wt/vol]) and boric acid (2% [wt/vol])
in methanol. The labeling mixture (80 l) was added to each sample (in 30
Longitudinal Persistence of the HIV Mannose Patch
December 2016 Volume 90 Number 24 jvi.asm.org 11133Journal of Virology







l of water) and incubated at 80°C for 1 h. The labeled oligosaccharides
were purified using Spe-ed amide-2 columns (Applied Separations, Allen-
town, PA) preequilibrated with acetonitrile. Before loading, 1 ml 97%
(vol/vol) acetonitrile was added to each sample. The loaded samples were
then washed with 2 ml 95% (vol/vol) acetonitrile and eluted with 1.5 ml
water. The glycans were dried under vacuum prior to ultraperformance
liquid chromatography (UPLC) analysis or glycosidase treatment.
Digestion of free labeled glycans. Glycan samples labeled with 2-AA
were digested overnight using endoglycosidase H (Endo H) (New Eng-
land Bioscience) in a total volume of 20 l. Samples were purified with a
protein-binding membrane cleanup, using a Ludger vacuum manifold
and a multiscreen filter protein-binding plate (Millipore).
Hydrophilic interaction liquid chromatography-ultraperformance
liquid chromatography. Glycans were separated by hydrophilic interac-
tion liquid chromatography (HILIC)-UPLC using a Waters Acquity sys-
tem (Waters, USA). The labeled samples were resuspended in 15 l water
and added to a vial with 15 l 100% acetonitrile. A 2.1-mm by 10-mm
Acquity BEH amide column (Waters; particle size, 1.7 m) with a pro-
grammed gradient was used for separation. Data were acquired and pro-
cessed with Empower 3 (Waters, USA).
Pseudovirus production and neutralization assays. To produce
pseudoviruses, plasmids encoding Env were cotransfected with an Env-
deficient genomic backbone plasmid (pSG3Env) in a 1:2 ratio with the
transfection reagent polyethyleneimine (PEI) (1 mg/ml; 1:3 PEI-total
DNA; Polysciences) into HEK 293T cells (obtained from the American
Type Culture Collection) (54, 55). Pseudoviruses were harvested 72 h
posttransfection for use in neutralization assays. Neutralizing activity was
assessed using a single-round replication pseudovirus assay with TZM-bl
target cells (provided by John Kappes through the NIH AIDS Reagents
Repository Program), as described previously (54, 55). Briefly, the anti-
body was serially diluted in a 96-well flat-bottom plate and preincu-
bated with virus for 1 h at 37°C. Cells at a concentration of 20,000/well
were added to the virus-antibody mixture, and the luminescence was
quantified 72 h following infection via lysis and addition of Bright-Glo
Luciferase substrate (Promega). Dose-response curves were fitted us-
ing nonlinear regression (GraphPad Prism) to determine 50% inhibi-
tory concentrations (IC50s).
Antibodies. PGT121, PGT128, PGT135, PG9, PGV04, VRC01,
PGT151, and CAP256-VRC26.25 were transiently expressed with the
FreeStyle 293 expression system (Thermofisher Scientific). The antibodies
were purified using affinity chromatography (Protein A Sepharose Fast
Flow; GE Healthcare), and the purity and integrity were checked by SDS-
PAGE.
Correlations and statistics. Correlations were determined using a
Pearson correlation and calculated using GraphPad Prism 6.
Preparation of chimeric viruses. Chimeric Env containing the C3V4
region were created using an overlapping PCR strategy and cloned into
the pCDNA 3.1D-TOPO vector (Invitrogen) as described previously (56).
The chimeric viruses were used to generate pseudoviruses as described
above and assayed for neutralization sensitivity to longitudinal CAP256
plasma (obtained from the CAPRISA cohort). Site-directed mutagenesis
was used to delete the N332 glycan within this construct to assess the role
of the glycan in mediating escape from plasma nAbs.
RESULTS
Longitudinal analysis of PNGSs and V loop lengths for CAP256
sequences. Env sequences from the CAP256 donor from multiple
time points over the course of HIV infection have been reported
previously (48, 49). Full Env single-genome amplification (SGA)
and next-generation sequencing of the V1-to-V3 region (using the
MiSeq platform) of viral variants from plasma samples correlated
well (48, 57). Here, 154 clones from multiple time points were
analyzed for their PNGS positions and frequencies, as well as their
variable-loop lengths. Previous studies have reported an increase
in PNGSs and variable-loop lengths over the course of HIV infec-
tion (44, 45). Therefore, we first determined whether these trends
were observed in CAP256 (Fig. 1). We first considered the changes
in variable-loop lengths over time. Although there was variation
in both the individual and total variable-loop lengths during the
course of infection, there were no notable correlations. However,
there was a weak negative correlation between total V loop length
and the number of weeks postinfection until week 94 (r 
0.2496; P  0.0039) (Fig. 1A). We next considered PNGS fre-
quency. For all CAP256 Env sequences, the frequency of gp41
PNGSs remained constant at 4, and the locations of these sites did
not change during the course of infection (Fig. 2). The frequency
of total PNGSs for gp120 ranged from 22 to 28, with the PI and SU
viruses having mostly 23 and 25 PNGSs, respectively (Fig. 1B).
The majority of variation in PNGS frequency occurred within
variable loops, in particular the V1/V2 loops and glycan sites po-
sitioned at the base of the V3 loop (N295, N332, and N334). When
the frequency of PNGSs was plotted against the number of weeks
postinfection, a weak positive correlation (r  0.21; P  0.01) was
observed. However, as the glycan shield is a dynamic entity that is
under constant pressure from the host immune system, we also
looked for correlations over shorter periods. In this donor, a
strong positive correlation (r  0.64; P  0.0001) was observed
until week 94, after which the number of PNGSs declined and
the correlation weakened (Fig. 1B). This decrease corre-
sponded predominantly to the loss of glycan sites at positions
N295 and N332. A slight decrease in PNGSs around weeks 30 to
34 was also observed, which corresponded to loss of V1/V2
loop PNGSs and the N289 or N295 glycan sites (Fig. 1B). In-
terestingly, this is the first time point at which the V1/V2-
specific antibody response was detected and subsequently led
to a sudden increase in viral diversification (48, 57). A similar
trend was observed for PNGSs on the OD (residues 252 to 482)
of gp120 until week 94; however, there was no correlation over
the full period (Fig. 1C). In summary, in the CAP256 donor,
there was a general trend toward increasing numbers of PNGSs
early in infection that decreased at the latest time point (week
176), which is consistent with previous studies (44, 45). How-
ever, there was still considerable variation between single vi-
ruses at a given time point (e.g., at week 176, the total numbers
of PNGSs differed by 4 [Fig. 1B]), enabling us to assess the
prevalence of the intrinsic mannose patch.
The intrinsic mannose patch is present on gp120 throughout
HIV infection in donor CAP256. To determine changes in the
composition of the HIV glycan shield and the abundance of oli-
gomannose-type glycans within the intrinsic mannose patch over
the course of infection, the gp120 regions of 24 CAP256 Envs from
different time points were recombinantly expressed. The selected
clones were chosen to represent major clades within a phyloge-
netic tree based on single-genome amplification. This smaller
sample of CAP256 Envs displayed a correlation between the num-
ber of weeks postinfection and PNGS frequency similar to that for
the 154 Env sequences (Fig. 1D to F), and their PNGS positions
and frequencies are shown in Fig. 2. We were particularly inter-
ested in the abundance of oligomannose-type glycans of the in-
trinsic mannose patch, as these glycans form part of the epitopes
of a number of the most broad and potent HIV bnAbs (e.g.,
PGT121, PGT128, and PG9) (5, 25, 58, 59). As we have previously
shown that the intrinsic mannose patch of recombinant gp120
captures much of the steric constraints exhibited by these glycans
in the context of the trimer (including SOSIP trimers) (7, 15, 17,
Coss et al.
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18, 22), monomeric gp120 was used as a useful model of this viral
feature. Residues 1 to 517 were cloned into a recombinant expres-
sion vector (pHLSec) (50, 51) and expressed in HEK 293F cells for
glycan profiling (we have previously shown that the mannose
patch is largely independent of the producer cell [17, 18]). The
protein constructs included a C-terminal hexahistidine tag so that
nickel affinity purification could be used to avoid potential bias
associated with other glycan-specific purification methods, such
as lectins. Proteins were purified first using His tag affinity chro-
matography, followed by SEC to remove aggregates. The purified
proteins were then run on a nonreducing SDS-PAGE gel, and the
monomeric gp120 band was excised for glycan analysis. N-linked
glycans were released using PNGase F, fluorescently labeled, and
analyzed by HILIC-UPLC. The percentage of oligomannose gly-
cans was assessed by integration of chromatograms pre- and post-
Endo H digestion, generating specific percentage areas for the oli-
gomannose glycans (Fig. 3A). It was then possible to assign
structures based on previous analysis (16, 18).
All gp120 samples displayed an intrinsic mannose patch; how-
ever, the population of oligomannose-type glycans varied from
29.3% to 47.6% (see Table S1 in the supplemental material). The
percent changes in oligomannose levels between gp120 94wks.A3,
which has the highest number of PNGSs (a total of 28), and
6wks_PI, which has the fewest PNGSs (a total of 23), are 27% and
212% for Man5–9GlcNAc2 and Man9GlcNAc2, respectively. gp120
94wks.A3 has additional PNGSs in V1 (N135 and N160), in C2
(N230), in C3 (N362), and in V4 (N406, N413), whereas 6wks_PI
has an additional PNGS in C4 (N442). We have previously mea-
sured the decrease in oligomannose-type glycans on BaL gp120
when one or two PNGSs were removed through Asn-to-Ala sub-
stitution (16). The largest effect was observed for the N295A/
N386A double mutant, where the percentages of Man5–9GlcNAc2
and Man9GlcNAc2 decreased by 27% and 71%, respectively.
Therefore, compared to our previous observations, the differ-
ences in oligomannose-type glycan abundances for 94wks.A3
and 6wks_PI are relatively small considering that these recom-
binant proteins differ by five PNGSs (16), but the difference in
Man9GlcNAc2 structures is much higher. This observation was
not unexpected, given that the positions of two of the additional
PNGSs are on the gp120 OD, where PNGSs are tightly clustered
(see Discussion below). This therefore suggests that there are re-
gions on gp120 where multiple glycans can be removed with little
impact on glycan processing of the intrinsic mannose patch and
that it is the local density of PNGSs that determines the extent of
glycan processing.
The abundance of oligomannose-type glycans correlates
with the density of PNGSs. To determine factors that might in-
fluence the abundance of specific oligomannose-type glycans on
gp120, we correlated the percentage of Man5–9GlcNAc2 glycans
with the total number of PNGSs on gp120 (Fig. 3B). A positive
correlation was observed (r  0.486; P  0.016), and this correla-
tion became more significant when only Man9GlcNAc2 glycan
abundance was considered (r  0.695; P  0.0002). When the
percentages of Man5–9GlcNAc2 and Man9GlcNAc2 were corre-
FIG 1 (A to C) Correlation between number of weeks postinfection and total length of variable loops (number of amino acids) (V1 to V5) (A), total
number of PNGSs on gp120 (B), and number of PNGSs on the gp120 outer domain (residues 252 to 482) (C). A total of 154 previously published Env
sequences over multiple time points were used in the analysis (48). (D to F) Correlation between the number of weeks postinfection and the total length
of variable loops (V1 to V5) (D), the total number of PNGSs on gp120 (E), and the number of PNGSs on the gp120 outer domain (residues 252 to 482)
(F) for the 24 recombinantly expressed gp120s. The PI virus and SU virus were at weeks 6 and 15, respectively. Correlations were assessed by Pearson
analyses; P values and r values are indicated between weeks 6 and 94 and between weeks 6 and 176 (All). Note that some of the sequences have identical
PNGS, OD PNGS, and V loop lengths, and these points are overlaid.
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lated with the frequency of PNGSs present only on the OD of
gp120, a strong positive correlation was observed for both
Man5–9GlcNAc2 and Man9GlcNAc2 (r  0.752, P   0.0001, and
r  0.717, P   0.0001, respectively) (Fig. 3C). The gp120 OD
PNGSs include many of the sites shown to be oligomannose type
in site-specific analysis studies (8, 11, 14, 22, 60). Further, the
recent crystal structures of the BG505 SOSIP.664 recombinant
trimer showed that the PNGSs in the region cluster tightly on the
surface of Env (58, 61). Therefore, an increase in PNGSs on
the outer domain of gp120 will likely further restrict access of the
glycan-processing enzymes, leading to an increase in oligoman-
nose-type glycans on gp120 and in the size of the intrinsic man-
FIG 2 Summary of PNGSs for 24 representative CAP256 Env clones that were expressed recombinantly. The total number of PNGSs on gp160, gp120, the outer
domain, V1/V2, V3/V4, and gp41 were calculated for each clone. Clones are grouped together according to the time they were isolated.
Coss et al.
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nose patch (7, 17). Interestingly, some gp120s that have the same
positioning and frequency of PNGSs still showed differences in
the percentages of oligomannose-type glycans, highlighting the
role the protein sequence may also play in determining the struc-
ture of the HIV glycan shield. For example, 59wks.2a and
59wks.10b have identical PNGSs, yet the percentages of oligoman-
nose-type glycans differ by 3.6%.
Longer variable-loop lengths might be expected to decrease the
density of PNGSs and lead to a higher degree of glycan processing
and therefore to a reduction in oligomannose-type glycans. Al-
though the CAP256 gp120 sequences differed in combined vari-
able-loop lengths by up to 20 amino acids, no correlation was
observed between oligomannose abundance and variable-loop
length (Fig. 3D), suggesting that the positioning of specific glycan
sites is most critical to oligomannose abundance.
The abundance of oligomannose-type glycans correlates
with the density of outer-domain PNGSs for a cross-clade panel
of gp120s. To determine whether the correlation between the
number of PNGSs on the outer domain of gp120 and the abun-
dance of oligomannose-type glycans was a general feature for HIV
Env across geographical clades, a panel of 29 gp120s were cloned,
expressed, and purified as described above. The panel included
gp120s from clades A, B, C, AE, and G, five of which were trans-
mitted/founder viruses. All the isolates tested were found to pos-
sess a significant population of oligomannose-type glycans rang-
ing from 23.8% to 50.5% (Fig. 4; see Table S2 in the supplemental
material). When the abundance of oligomannose-type glycans
was correlated with the total number of PNGSs (ranging from 21
to 28), no significant correlation was observed (Fig. 4A). However,
a significant correlation was observed between the frequency of
OD PNGSs (ranging from 12 to 17) and oligomannose abun-
dance, similar to that seen for the CAP256 samples (r  0.4692;
P  0.010) (Fig. 4B). No significant correlations were observed
between total PNGSs or OD PNGSs and Man9GlcNAc2 (data not
shown). These data further support the notion that a high density
of PNGSs on the OD restricts glycan-processing enzymes, leading
to a larger population of underprocessed oligomannose-type gly-
cans. These data also suggest that it is local glycan density that has
the largest impact on glycan processing, rather than overall glycan
density. Interestingly, the specific occupancy and composition of
individual sites was not assessed here, but this could be an infor-
mative extension in future studies.
While there are variations in the percentages of certain oligo-
mannose structures between the clades (clades C and G have fewer
Man9GlcNAc2 structures, and clade C has fewer Man8GlcNAc2
structures), the overall abundances of oligomannose glycans are
fairly similar (Fig. 4C and D). Clade C has the lowest total percent-
age of oligomannose (35.5%), yet compared to clade B, with one
of the highest percentages and lowest standard deviation (SD)
(38.5%; SD, 4.98), there is no significant difference between the
two (Fig. 4C), although this difference might become more signif-
icant if more gp120s were studied. Considering the correlation
between outer-domain PNGSs and Man5–9GlcNAc2, it is likely
that loss of specific sites between clades is responsible for the dif-
ferences in specific glycan abundance. This is particularly relevant
for clade C viruses, which typically lack the N295 glycan site (62,
63), a PNGS we have previously shown to stabilize the mannose
patch from glycan processing (16). However, while there are some
differences in the structures, the total levels of oligomannose-type
glycans remain similar between clades, indicating the overall sta-
bility and conserved nature of the mannose patch.
Correlation of oligomannose-type glycans with time postin-
fection. We next examined how the size of the intrinsic mannose
patch changes over the course of HIV infection. We first corre-
FIG 3 (A) HILIC-UPLC spectrum of fluorescently labeled N-linked glycans released from 48wks.17 gp120 using PNGase F presented as an example of the
quantification methodology. The green trace is a spectrum of released glycans, and the white trace is the spectrum for Endo H-treated glycans. Overlaying of the
spectra resulted in the glycans sensitive to Endo H being displayed as green. M5–M9 refers to Man5–9GlcNAc2. (B to D) The percentage of oligomannose glycans
was assessed by integration of chromatograms pre- and post-Endo H digestion, generating specific percentage areas for the oligomannose glycans. The
oligomannose glycans are highlighted. Shown are correlations between the abundances of oligomannose-type glycans (Man5–9GlcNAc2 and Man9GlcNAc2) and
total PNGSs on gp120 (B), PNGSs on the gp120 outer domain (residues 252 to 482), and total variable-loop lengths (D). The correlations were assessed by
Pearson analyses; P values and r values are indicated.
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lated the percentage of oligomannose-type glycans with the num-
ber of weeks postinfection, but no correlation was observed (Fig.
5A). As the glycan shield is a dynamic entity that is under constant
pressure from the host immune system, we also looked for corre-
lations over shorter periods to reflect this. We observed correla-
tions between Man5–9GlcNAc2 and Man9GlcNAc2 abundance and
the number of weeks postinfection until week 94 (r  0.513, P 
0.025, and r  0.666, P  0.0019, respectively) (Fig. 5A) similar to
that seen for changes in PNGS frequency over time. The abun-
dance of oligomannose-type glycans, then, largely persists but ex-
hibits some variation due to sensitivity to loss of PNGSs at the base
of V3, in particular at positions N295 and N332/N334 (Fig. 2).
To analyze the changes in Env glycan composition over time in
more detail, we next determined the percent change in total oli-
gomannose-type glycans (Man5–9GlcNAc2) and Man9GlcNAc2
individually for each gp120 clone (Fig. 5B). As the viral popula-
tion early in infection was predominantly made up of the SU virus,
with only the V1/V2 and gp41 C terminus mostly being derived
from the PI virus, changes in total Man5–9GlcNAc2 and
Man9GlcNAc2 composition were considered in relation to the SU
virus. Although the mannose patch is present on all CAP256 pro-
teins studied, the changes in Man5–9GlcNAc2 and Man9GlcNAc2
can vary for individual clones at a given time point. Generally, a
large increase in oligomannose-type glycans was due to increases
in Man8GlcNAc2 and Man9GlcNAc2 early-stage glycan structures
(Fig. 5B; see Table S1 in the supplemental material), further sug-
gesting that increased density in PNGSs leads to reduced glycan
processing. For example, gp120s from weeks 59 and 94, which had
the highest oligomannose-type glycan abundance (44.0 to 47.6%),
had 28.4% to 30.4% Man8 –9GlcNAc2 structures. Interestingly,
previous analysis of glycan site mutants showed that the presence
of Man9GlcNAc2 was particularly dependent on multiple stabiliz-
ing interactions with neighboring glycans (16).
The abundance of oligomannose-type glycans does not cor-
relate with the neutralization potency of anti-HIV bnAbs. We
next wanted to determine whether the structure of the HIV glycan
shield, in particular the abundance of oligomannose-type glycans,
might influence the potency of neutralization by a panel of HIV
bnAbs. We therefore determined the IC50s for the intrinsic man-
nose patch binding bnAbs PGT121, PGT128, and PGT135; the
V1/V2 loop bnAb PG9 and several members of the CAP256-
VRC26 antibody lineage; cleavage-specific bnAb PGT151; and
CD4 binding site bnAbs PGV04, VRC01, and llama antibody
VHH J3 (see Table S3 in the supplemental material). When the
IC50s were correlated with the abundances of oligomannose-type
glycans, no significant correlations were observed for any bnAbs
(Fig. 6), although a general weak trend for increasing IC50s with
increasing oligomannose-type glycans was observed for some
bnAbs. Generally, the ability of a bnAb to neutralize a viral variant
was dependent on the presence of key contact glycan sites, such as
N160 or N332. The majority of viruses were resistant to PGT135
neutralization, and viruses lacking the N332 glycan site, and in
FIG 4 (A and B) Correlation between the percentage of oligomannose-type glycans (Man5–9GlcNAc2) and total number of PNGSs on gp120 (A) and PNGSs on
the outer domain of gp120 (residues 252 to 482) (B) for a cross-clade panel of gp120 glycoproteins. Each point is colored depending on the HIV clade (A, n 
7; B, n  8; C, n  6; AE, n  4; and G, n  4). The correlations were assessed by Pearson analyses; P values and r values are indicated. (C and D) Cross-clade gp120
panel differences for Man5-Man9 and Man9 (C) and total PNGSs and OD PNGSs (D). The error bars represent standard deviations. A Mann-Whitney test was
used to show that there were no significant differences between the groups.
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one case the N295 glycan site, were resistant to PGT128. PGT121
was able to neutralize all but two viruses. PG9 could not neutralize
viruses lacking the N160 glycan site or viruses with a glutamic acid
at position 169 (Fig. 2 and 6; see Table S3 in the supplemental
material) (48), whereas CAP256-VRC26 lineage bnAbs were de-
pendent on protein residues in V1 for neutralization (27). Inter-
estingly, none of CAP256-VRC26 lineage bnAbs isolated over sev-
eral different time points throughout infection (weeks 119, 159,
193, and 206) showed any correlation with oligomannose abun-
dance, suggesting that increasing the size of the mannose patch is
not a direct mechanism of escape against the autologous antibod-
ies in this donor. For PGT151, although all the viruses contained
the key glycan sites and residues thought to be required for neu-
tralization (N611, N637, and E647), some viruses were nonethe-
less resistant to PGT151 neutralization. The potencies for the CD4
binding site bnAbs PGV04, VRC01, and J3, which do not contact
glycans, generally did not correlate with the levels of oligoman-
nose-type glycans. As N-linked glycans are positioned around the
edge of the CD4 binding site, the changes in bulk glycan structures
observed may not occur in this region of gp120 and therefore may
not impact CD4 binding site bnAbs, but site-specific glycan anal-
ysis would be required to determine this. Interestingly, the smaller
single-chain llama antibody, J3, had the smallest variation in
IC50s. Therefore, the abundance of oligomannose-type glycans in
the intrinsic mannose patch does not impact the potency of neu-
tralization and suggests Env sequences from any time point during
infection, provided they have the key contact glycan sites, would
be suitable HIV immunogens.
Anti-C3V4 nAbs may be responsible for loss of PNGSs at
week 176. The loss of glycan sites at the base of the V3 loop at
week 176 suggested that neutralizing antibodies might exert
selection pressure against this region that leads to loss of
FIG 5 (A) Correlation between number of weeks postinfection and abun-
dances of Man5–9GlcNAc2 and Man9GlcNAc2. (B) Percent change in
Man5–9GlcNAc2 and Man9GlcNAc2 compared to the SU virus for each
CAP256 gp120 clone studied {percent change  [(percent CAP  percent
SU)/percent SU]  100}. The correlations were assessed by Pearson anal-
yses; P values and r values are indicated.
FIG 6 Correlation between the potency of neutralization (IC50s) and the percentage of oligomannose-type glycans (M5–M9, Man5–9GlcNAc2) for a panel of HIV
bnAbs: N332-dependent (intrinsic mannose patch binding) bnAbs, CD4 binding site bnAbs, PGT151, and N160 V1/V2 loop bnAbs. The correlations were
assessed by Pearson analyses. The IC50s are listed in Table S3 in the supplemental material.
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PNGSs and a decrease in abundance of oligomannose-type gly-
cans. To assess whether the region was a target of nAbs, we
created a chimeric Env from the 176wks.4 Env, which had al-
ready escaped the high-titer V2 responses that dominate
CAP256 plasma (49). Using overlapping PCR, we transferred
the C3V4 region from the sensitive 15wks_SU virus into the
resistant backbone and tested this chimeric Env (15wks_SU
C3V4) against longitudinal plasma (Fig. 7). Anti-C3V4 anti-
bodies at titers greater than 1:100 were detected from 42 weeks
postinfection, persisting at least until 94 weeks, at which time
point an additional specificity emerged. To determine whether
the anti-C3V4 antibodies were directed against the N332 gly-
can site in particular, we next used site-directed mutagenesis
to make an Asn-to-Ala substitution at the N332 glycan site
(15wks_SU C3V4 N332A). A decrease in serum titers was ob-
served, indicating that some of the C3V4 antibody response is
directed against the N332 epitope (Fig. 7). The presence of
anti-C3V4 nAbs suggests that nAbs against the region can elicit
a selective pressure that results in loss of V3 loop glycans and a
subsequent decrease in oligomannose-type glycans.
DISCUSSION
It is clear that the HIV glycan shield is under constant pressure
from the host immune system. Here, we used longitudinal Env
sequences from a chronically infected HIV patient to characterize
the changes in the structure of the HIV glycan shield during the
course of HIV infection, in particular the persistence and compo-
sition of the intrinsic mannose patch. We showed that in the
CAP256 donor, the mannose patch (Fig. 8A) persists throughout
infection despite the variation in PNGS position and frequency
(Fig. 8B). In this donor, there is an increase in PNGSs and oligo-
mannose-type glycans within the intrinsic mannose patch over
the course of infection until week 94. This increase correlates with
the frequency of PNGSs on the outer domain. Thereafter, there is
a reduction in PNGSs at the base of V3 and a corresponding re-
duction in oligomannose-type glycans by week 176, likely a con-
sequence of viral escape from a de novo neutralizing response to
the C3V4 region. Although this study focuses on only one donor,
these findings give insight into the composition and conservation
of the intrinsic mannose patch under immune pressure and high-
light the epitope as an important target for HIV vaccine design
strategies.
Our previous studies have shown that the glycosylation of
HIV Env is determined by both protein-directed effects, arising
from the 3-dimensional protein structure, and cell-directed
effects, arising from the cell type the protein is expressed in (2,
17, 18). The protein-directed effects give rise to a patch of
underprocessed oligomannose-type glycans on the outer do-
main of gp120 that forms a nonself epitope targeted by HIV
bnAbs. We show that despite the variation in the protein se-
quence and the positioning and frequency of PNGSs, the in-
trinsic mannose patch is highly conserved during the course of
infection in the CAP256 donor and therefore represents a sta-
ble target for vaccine design. However, the intrinsic mannose
patch varies in both overall size and distribution of glycans
within the oligomannose series (Man5–9GlcNAc2), and this
most strongly correlates with the density of PNGSs present on
the OD of gp120. This trend was also observed, although to a
lesser extent, for a cross-clade panel of gp120s and highlights
the role the protein sequence might also play in determining
the structure of the HIV glycan shield. These data support our
previous conclusions that the high density of PNGSs restricts
glycan-processing enzymes from trimming and processing N-
linked glycans within the region (7, 15, 16, 18, 64). Interest-
ingly, it seems to be the local glycan density rather than the
overall glycan density that has the biggest impact on the size
and composition of the mannose patch. Although Env se-
FIG 7 Kinetics of the C3V4 neutralizing antibody response in CAP256. Titers
are shown using the CAP256 176wks.4 virus and chimeric Envs containing
only the C3V4 region of the sensitive SU virus (15wks_SU C3V4) and an
N332A variant (15wks_SU C3V4 N332A). Anti-C3V4 antibodies at titers
greater than 1:100 were detected from 42 weeks postinfection and persisted at
least until 94 weeks postinfection. The anti-C3V4 antibodies show some
N332A dependence. Titers are indicated as plasma 50% infective dose (ID50)
versus number of weeks postinfection.
FIG 8 Schematic representation of the evolving HIV glycan shield. (A) Structure of BG505 SOSIP.644 trimer showing the presence of the intrinsic mannose
patch (IMP) (green) present on one of the three gp120 monomers (22, 72). (B) Cartoon representation of the longitudinal evolution of the intrinsic mannose
patch on gp120. Despite the changes in position and frequency of PNGSs on gp120, the intrinsic mannose patch persisted throughout infection in this individual.
The green area represents the intrinsic mannose patch from one gp120 monomer.
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quences vary by up to 5 PNGSs, it is clear that it is mainly
PNGSs within and around the outer domain of gp120 that
affect the size and distribution of oligomannose-type glycans
within the intrinsic mannose patch. The potency of neutraliza-
tion by a panel of HIV bnAbs is not affected by the variation in
mannose patch composition but is dependent on the presence
of certain key PNGSs. This suggests that PNGSs on gp120 have
sufficiently high density that the natural variation in Env oc-
curring throughout infection has minimal impact on glycan
processing, so that the mannose patch, which is intrinsic to
both the monomer and the trimer, is always present. Therefore,
the density of glycans on gp120, even at the lowest density, is
sufficient to maintain the steric restriction necessary to impede
mannosidase processing. This is consistent with previous ob-
servations suggesting that minimal glycan-glycan interactions
are required to prevent processing to complex-type glycans
(16). In addition, this effect may be further compounded by the
trimer-associated restriction of processing not captured by our
monomeric gp120 model (1, 2, 18, 22). Although several stud-
ies have reported more compact transmitter clade C and A
viruses (39, 40), with shorter V1-to-V4 loop lengths, this does
not appear to impact the glycosylation of gp120s from the
CAP256 donor.
The most dramatic changes to the HIV glycan shield of
CAP256 gp120 occur when glycans at the base of the V3 loop
are added or deleted. This is supported by our previous studies
showing that deletion of glycans within this region for gp120BaL
had the largest impact on oligomannose-type glycan abun-
dance due to disruption of glycan microclusters within the
outer domain (16). We have shown that some of the changes
occurring in the PNGS position and frequency of CAP256
gp120, and subsequently oligomannose abundance, at week
176 postinfection are likely a result of a new wave of neutraliz-
ing antibodies targeting the C3V4 region, including the N332
glycan. These data may suggest that the selective pressure of
neutralizing Abs targeting the intrinsic mannose patch would
have the biggest effect on shaping the glycan structures present
on the HIV glycan shield. Unfortunately, full-length Envs from
later time points were not available, but as the C3V4-specific
response arose after approximately 75 weeks, any additional
destabilization of the intrinsic mannose patch is likely to occur
within the time frame studied. It is possible that if a similar
study were carried out in a donor who developed bnAbs against
another epitope, such as the CD4 binding site, less variation in
OD PNGS frequency would occur, and thus, a smaller variation
in oligomannose-type glycans would be observed over the
course of infection.
Go and colleagues have previously compared the glycosyla-
tion of recombinant gp120 from transmitted/founder (t/f) vi-
ruses and chronic viruses (60). They concluded that t/f virus
Envs are more similar to each other than to those of their cor-
responding chronic viruses, with t/f Envs having distinct gly-
cosylation patterns consisting of higher levels of oligomannose
and sialylated glycans and a lower site occupancy (60). How-
ever, the study was limited, as only two t/f and two chronic
viruses were studied, and these viruses were not derived from
the same donors. Indeed, comparison of oligomannose levels
on the t/f and chronic viruses in our gp120 panel showed no
significant differences. By using longitudinal virus sequences,
we were able to show that over the course of infection in the
CAP256 individual, there was an increase in PNGSs and a cor-
responding increase in oligomannose-type glycans that were
subsequently reduced by the pressure of neutralizing antibod-
ies. Although the PI and SU virus gp120s have lower levels of
oligomannose-type glycans (35.3% and 36.4%, respectively)
than the majority of gp120s from later time points, there are
viruses within the quasispecies that have lower levels of oligo-
mannose glycans, e.g., 38wks.38 and 48wks.10, with 32.7% and
35.5% oligomannose-type glycans, respectively. It would be
interesting to determine the glycosylation of Envs within the
HIV-infected donor who transmitted the viruses to the
CAP256 donor; however, these samples are not available.
Although we have studied only one HIV-infected individual
in detail, a number of studies have shown that t/f viruses have a
lower frequency of PNGSs (39–43). Whether there would be a
benefit for t/f viruses to have a reduced frequency of PNGSs and
subsequently to display a lower proportion of oligomannose-
type glycans is unclear. In relation to HIV transmission, studies
have shown that the importance of the interaction of DC-SIGN
receptors on dendritic cells (DCs) in mucosal tissues for trans-
fection of CD4 T cells is strongly dependent on the presence
of oligomannose structures (65–67). In relation to infectivity,
reduction of complex-type glycans on HIV virions (through
the use of glycosidase inhibitors or a GnTI-deficient cell line)
reduced the infectivity of the virus but enhanced transinfection
of peripheral blood lymphoctyes (32, 68). In relation to Env
immunogenicity, studies have shown that removal or occlusion
of mannose residues from the surface of gp120 can enhance the
immune response against HIV due to reduced interactions
with immunosuppressive receptors, such as the mannose re-
ceptor (69–71). Taken together, these studies might suggest
that a higher abundance of oligomannose-type glycans would
be more beneficial for transmitted viruses. It is therefore pos-
sible that the reduced oligomannose levels in the PI and SU
viruses are only a consequence of fewer PNGSs and do not give
a virus a competitive advantage at the point of transmission.
However, there may be a tradeoff between viral infectivity and
host recognition. Regardless, in terms of vaccine design, Env-
based immunogens with a lower abundance of oligomannose-
type glycans (for the CAP256 donor, this would be Envs from
earlier time points) might give a stronger immune response, as
suggested by the studies described above (69–71).
In summary, although in the CAP256 donor there were
changes in both the frequency and positioning of PNGSs due to
immune pressure, the intrinsic mannose patch remained a sta-
ble feature of HIV Env and was present throughout the course
of HIV infection. The density of PNGSs on the outer domain of
gp120 can influence the size and composition of the intrinsic
mannose patch, but these differences do not affect the neutral-
ization sensitivity of a panel of HIV bnAbs. These findings, in
addition to our previous observations showing the presence of
the intrinsic mannose patch to be independent of producer
cells, further highlight the mannose patch as a stable target for
HIV vaccine design.
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